CITY OF INDUSTRY, Calif., Feb. 28 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. recently attended the Cambridge Healthtech Institute’s Thirteenth International Molecular Medicine Tri-Conference Stem Cell Track hosted in San Francisco.
Director of Research, Dr. Cyndi Chen was in attendance for the Stem Cell Track entitled “Commercial Implication of Stem Cell Research” and networked with key figures to build awareness of the company’s stem cell research initiative. The meeting included seminars from Dr. Stephen Minger, Director of the Stem Cell Biology Laboratory at King’s College London and Dr. Mark Levenstein of WiCell Research Institute. The meeting highlighted new areas of discovery and the therapeutic strategies and potentials of stem cell research.
For additional exciting information about stem cell potential, supporters are encouraged to read the article, “Scientist Hopes for Stem Cell Success” and the recent “60 Minute” segment on regenerative medicine. The show focused on the recent finding by Dr. Keirstead, a 38-year-old biologist at the University of California, Irvine in treating spinal cord injuries using stem cells, in collaboration with Geron. Other Stem Cell researchers highlighted include Stem Cells, Inc. and Dr. Arnold Kriegstein of UC San Francisco.
Forward-Looking Statements
Included in this release are certain “forward-looking” statements involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements.
Contact Information: U.S. BioDefense, Inc. David Chin, 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.
CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
